Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANAB 
AnaptysBio Inc (ANAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: ANAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $65.73
1 Year Target Price $65.73
| 7 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.65% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 65.73 |
Price to earnings Ratio - | 1Y Target Price 65.73 | ||
Volume (30-day avg) 12 | Beta 0.3 | 52 Weeks Range 12.21 - 38.38 | Updated Date 11/4/2025 |
52 Weeks Range 12.21 - 38.38 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.39 |
Earnings Date
Report Date 2025-11-11 | When - | Estimate -1.44 | Actual - |
Profitability
Profit Margin -107.66% | Operating Margin (TTM) -117.55% |
Management Effectiveness
Return on Assets (TTM) -14.12% | Return on Equity (TTM) -343.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 626059725 | Price to Sales(TTM) 8.19 |
Enterprise Value 626059725 | Price to Sales(TTM) 8.19 | ||
Enterprise Value to Revenue 5.08 | Enterprise Value to EBITDA -1.3 | Shares Outstanding 27972997 | Shares Floating 14557021 |
Shares Outstanding 27972997 | Shares Floating 14557021 | ||
Percent Insiders 5.83 | Percent Institutions 131.28 |
Upturn AI SWOT
AnaptysBio Inc
Company Overview
History and Background
AnaptysBio Inc. was founded in 2005. It is a clinical-stage biotechnology company committed to delivering meaningful therapeutic impact in diseases where there is significant unmet need. They initially focused on antibody discovery, then transitioned to developing their own pipeline of therapeutic antibodies.
Core Business Areas
- Antibody Discovery: Discovery and development of therapeutic antibodies for inflammation, immuno-oncology, and other disease areas. Historically, this included out-licensing activities.
- Proprietary Pipeline Development: Focusing on developing proprietary antibody candidates, advancing them through clinical trials for potential commercialization. Currently, they are focused on imsidolimab development.
Leadership and Structure
Daniel Faga is the President and Chief Executive Officer. The company has a Board of Directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- Imsidolimab: An anti-IL-36R antibody in development for the treatment of generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP), and acne. Competition includes drugs that target IL-17 or IL-23.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. There is a growing focus on precision medicine and targeted therapies.
Positioning
AnaptysBio focuses on novel antibody therapeutics. Its competitive advantage lies in its antibody discovery platform and potential for first-in-class or best-in-class therapies.
Total Addressable Market (TAM)
TAM for GPP and PPP indications are estimated in the billions of dollars. AnaptysBio's position depends on clinical trial success and eventual market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform
- Potential first-in-class antibody candidates
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on clinical trial outcomes
- Limited product pipeline
- Dependence on financing for R&D
- No currently marketed products
Opportunities
- Successful clinical trials leading to regulatory approvals
- Expansion of pipeline through additional antibody candidates
- Partnerships with larger pharmaceutical companies
- Potential for acquisitions
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory environment
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- MRK
- ABBV
Competitive Landscape
AnaptysBio competes with established pharmaceutical companies developing treatments for inflammatory diseases. Its advantage lies in novel antibody targets.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancing antibody candidates through preclinical and clinical development.
Future Projections: Future growth is contingent on successful clinical trials and potential commercialization or partnerships.
Recent Initiatives: Focus on developing imsidolimab for GPP, PPP, and acne.
Summary
AnaptysBio is a clinical-stage biotech company with a focus on antibody therapeutics. Its future success hinges on the positive results from ongoing clinical trials. While they have a proprietary platform and an interesting drug pipeline, they need to carefully manage their finances due to high research and development costs and competition from pharmaceutical giants.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AnaptysBio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2017-01-26 | President, CEO & Director Mr. Daniel R. Faga | ||
Sector Healthcare | Industry Biotechnology | Full time employees 136 | Website https://www.anaptysbio.com |
Full time employees 136 | Website https://www.anaptysbio.com | ||
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.